Revenue Recognition (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 31, 2023 USD ($) item	Feb. 28, 2019 USD ($)	Sep. 30, 2025 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2025 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Disaggregation of Revenue [Line Items]
Increased (decreased) revenues					$ (8,700)	$ (7,700)
(Increased) decreased net loss					$ (8,700)	$ (7,700)
(Increased) decreased net loss per share | $ / shares					$ (0.06)	$ (0.06)
Other assets			$ 70,675		$ 70,675		$ 36,720
Deferred revenue			38,230	$ 34,802	$ 38,230	$ 34,802	36,592	$ 35,740
Product
Disaggregation of Revenue [Line Items]
Approximate percentage of revenue collected within 9 months					90.00%
Billing collection period (in months)					9 months
Extended billing collection period (in months)					6 months
Increased (decreased) revenues			(2,900)	(2,600)
(Increased) decreased net loss			$ (2,900)	$ (2,600)
(Increased) decreased net loss per share | $ / shares			$ (0.02)	$ (0.02)
Tests delivered in prior periods that were fully collected
Disaggregation of Revenue [Line Items]
Increased (decreased) revenues			$ 55,100	$ 34,500	$ 134,700	108,100
(Increased) decreased net loss			$ 55,100	$ 34,500	$ 134,700	$ 108,100
(Increased) decreased net loss per share | $ / shares			$ 0.4	$ 0.28	$ 0.99	$ 0.88
Amounts not refunded to insurance carriers
Disaggregation of Revenue [Line Items]
Increased (decreased) revenues			$ 200	$ 400	$ 1,100	$ 4,400
(Increased) decreased net loss per share | $ / shares			$ 0.01	$ 0.01	$ 0.01	$ 0.04
BGI Genomics
Disaggregation of Revenue [Line Items]
Revenue recognized		$ 44,000
Agreement term		10 years
Revenue, remaining performance obligation		$ 6,000
Transaction price		50,000
Deferred revenue			$ 16,900		$ 16,900		$ 17,300
Prepaid royalties		$ 20,000
BGI Genomics | License and related development services
Disaggregation of Revenue [Line Items]
Number of performance obligations | item	2
Revenue, remaining performance obligation	$ 24,000
BGI Genomics | Oncology assay interpretation services
Disaggregation of Revenue [Line Items]
Revenue recognized					$ 400	$ 1,400
Revenue, remaining performance obligation								$ 20,000